CTIS2022-502207-30-00进行中（未招募）1 期
A Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients with Early Parkinson's Disease - CUV901
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patient diagnosed with PD less than three years prior to first screening visits and not yet requiring dopaminergic medication nor expected to within three months of enrolment., 40-85 years old
排除标准
- •History of drug abuse, licit or illicit., Participation in any clinical intervention study during the six weeks before the study screening period., Any medical condition or illness in the four weeks before the study screening which may interfere with the study protocol or not suitable for study participation in the opinion of the Investigator., Heavy alcohol consumption., Current cigarette smokers., Any personal or immediate family history of melanoma or personal history of dysplastic nevus syndrome, Known allergy or anaphylaxis to adrenocorticotropic hormone (ACTH) or melanocortins, Any evidence of hepatic insufficiency or renal impairment., Female who is pregnant or lactating., Females of child-bearing potential not using highly effective contraceptive measures, for up to three months after the last injection administration., Sexually active men with a partner of child-bearing potential who is not using highly effective contraceptive measures.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial in patients with renal cell cancer that have had at least one, but no more than three prior cancer treatments and their cancer has gotten worse or did not respond. The study is investigating the safety, tolerability, and clinical activity of investigational drugs MEDI0680 and Durvalumab. The study will look at the effect of these two drugs when given to patients in combination (given together) versus nivolumab given alone.EUCTR2016-000323-43-NLMedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC96
进行中（未招募）
1 期
A clinical trial in patients with renal cell cancer that have had at least one, but no more than three prior cancer treatments and their cancer has gotten worse or did not respond. The study is investigating the safety, tolerability, and clinical activity of investigational drugs MEDI0680 and Durvalumab. The study will look at the effect of these two drugs when given to patients in combination (given together) versus nivolumab given alone.clear-cell renal cell carcinomaMedDRA version: 20.0Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000072939EUCTR2016-000323-43-GBMedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC96
招募中
1 期
A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing TumorsHepatocellular Carcinoma (HCC)Other GPC3-expressing TumorsCancer - LiverACTRN12623000798662Boston Pharmaceuticals, Inc.81
已完成
2 期
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies10038364clear-cell renal cell carcinoma (ccRCC)kidney cancerNL-OMON47649MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC10
进行中（未招募）
1 期
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory MyopathyActive Idiopathic Inflammatory Myopathy including dermatomyositis, anti-synthetase syndrome, and immune-mediated necrotizing myopathyMusculoskeletal DiseasesISRCTN75158615Advanced Clinical18